Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs)
Biomolecules · 2025
DOI: 10.3390/biom15040511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Les P Jones und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA. Hauptthemen laut MEDLINE: Probenecid, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Mitogen-Activated Protein Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Georgia Research Alliance.
Abstract (Originalsprache)
Probenecid has long been a versatile drug in pharmacological therapies, primarily known for blocking active tubular secretion in the kidney, affecting both endogenous substances like uric acid and exogenous ones like penicillin. Beyond its renal applications, probenecid has shown capabilities in crossing the blood–brain barrier and modulating the activity of various membrane channels and transporters. This compound has emerged as a potent antiviral agent, demonstrating efficacy against multiple viruses, including influenza, COVID-19, and RSV. Clinical trials with COVID-19 patients have confirmed its antiviral potential, sparking further investigation into its mechanisms of action. This study explores probenecid’s significant anti-inflammatory properties, focusing on its ability to inhibit inflammasome activation. Our study aims to unravel the anti-inflammatory effects of probenecid on the NLRP3 inflammasome and MAPK signaling pathways using murine macrophages as a relevant inflammation model. We reveal that probenecid treatment blocks JNK and ERK signaling without affecting p38 MAPK, suppressing NLRP3 inflammasome activation. Additionally, probenecid does not affect NFκB-directed protein expression, although it efficiently inhibits NLRP3 inflammasome outputs, e.g., IL-1β and pyroptosis. These results indicate probenecid’s potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
- TrippBio, Inc., Jacksonville, FL 32256, USA.
- Department of Chemistry and Biochemistry, Florida Atlantic University, Jupiter, FL 33431, USA.
ORCID-Profile: David E Martin, Ralph A Tripp
Förderung
- Georgia Research Alliance
Zitieren
APA
Jones, L. P., Martin, D. E., Murray, J., Sancilio, F., & Tripp, R. A. (2025). Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs). Biomolecules. https://doi.org/10.3390/biom15040511
Vancouver
Jones LP, Martin DE, Murray J, Sancilio F, Tripp RA. Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs). Biomolecules. 2025. doi:10.3390/biom15040511
BibTeX
@article{Jones2025,
author = {Jones, Les P and Martin, David E and Murray, Jackelyn and Sancilio, Fred and Tripp, Ralph A},
title = {Probenecid Inhibits NLRP3 Inflammasome Activity and Mitogen-Activated Protein Kinases (MAPKs)},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15040511}
}
EUVIMED